Products for Research Use Only
RegisterLogin

Ralinepag

CAT: 0804-HY-16751-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-16751-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Ralinepag is a potent, orally bioavailable and non-prostanoid prostacyclin (IP) receptor agonist, with EC50s of 8.5 nM, 530 nM and 850 nM for human and rat IP receptor and human DP1 receptor, respectively.
CAS Number
1187856-49-0
Product Name Alternative
APD811
UNSPSC
12352005
Hazard Statement
H315-H319-H335
Target
Prostaglandin Receptor
Type
Reference compound
Related Pathways
GPCR/G Protein
Applications
COVID-19-immunoregulation
Field of Research
Cardiovascular Disease; Endocrinology
Assay Protocol
https://www.medchemexpress.com/Ralinepag.html
Purity
99.79
Solubility
DMSO : ≥ 100 mg/mL
Smiles
O=C(O)COC[C@H]1CC[C@H](COC(N(C2=CC=C(Cl)C=C2)C3=CC=CC=C3)=O)CC1
Molecular Formula
C23H26ClNO5
Molecular Weight
431.91
Precautions
P261-P264-P271-P280-P302+P352-P304+P340-P305+P351+P338-P362-P403+P233-P405-P501
References & Citations
[1]Tran TA, et al. Discovery of 2- (((1r,4r) -4- (((4-Chlorophenyl) (phenyl) carbamoyl) oxy) methyl) cyclohexyl) methoxy) acetate (Ralinepag) : An Orally Active Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension. J Med Chem. 2017 Feb 9;60 (3) :913-927.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 3
Isoform
DP; IP

Alternative Products

CatalogName
BA5707-5.1Ralinepag
A21073-100Ralinepag 100mg
A21073-50Ralinepag 50mg
A21073-10Ralinepag 10mg
A21073-1Ralinepag 1mg
A21073-500Ralinepag 500mg
A21073-25Ralinepag 25mg
A21073-5Ralinepag 5mg
A21073-10mM-DRalinepag 10mM * 1mL in DMSO

Popular Products